131587-27-4

Basic information

• Product Name: N-(1-benzyl-4-piperidinyl)-N-(4-fluorophenyl)amine
• Synonyms: N-(1-benzyl-4-piperidinyl)-N-(4-fluorophenyl)amine;para-fluoro 4-ANBP
• CAS NO: 131587-27-4
• Molecular Formula: C₁₈H₂₁FN₂
• Molecular Weight: 284.3711432
• Mol File: 131587-27-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 404.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.160±0.06 g/cm3(Predicted)
• PKA: 8.17±0.10(Predicted)
• CAS DataBase Reference: N-(1-benzyl-4-piperidinyl)-N-(4-fluorophenyl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-benzyl-4-piperidinyl)-N-(4-fluorophenyl)amine(131587-27-4)
• EPA Substance Registry System: N-(1-benzyl-4-piperidinyl)-N-(4-fluorophenyl)amine(131587-27-4)

Safety Data

• Hazardous Substances Data: 131587-27-4(Hazardous Substances Data)

Upstream product

• 4783-65-7 N-benzyl-2-piperidinone 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 639505-48-9 C₁₈H₂₀FN₃O 
• 202859-51-6 N-(4-fluorophenyl)-N-(piperidin-4-yl)propionamide 
• 202859-28-7 N-(1-benzylpiperidin-4-yl)-N-(4-fluorophenyl)propionamide 

Relevant articles and documents

NOVEL PIPERIDINE-SUBSTITUTED INDOLES- OR HETERODERIVATIVES THEREOF

Accordingly, one object of the present invention are novel piperidine-substituted indoles- or heteroderivatives thereof of the formula(1) wherein R, R, R, A, B, D-E, X-W-V, Y, i, j, n and m are defined as below. Another object of the present inve

Pharmacological profile of a novel series of NK1, antagonists. In vitro and in vivo potency of benzimidazolone derivatives

By low throughput examination of our chemical library, compound 7 was selected as a lead NK1, antagonist with a K(i) of 7.1 nM. Modifications of its structure led to the finding that the in vitro potency could be markedly enhanced by disubstituting the anilino phenyl ring as in compounds 13 or 22. Human binding data correlated rather well with results obtained with in vitro animal smooth muscle preparations. Several agents proved to possess antinociceptive properties as exemplified in the hot-plate test in mice; compound 13 was the most active with ED50 of 0.001 and 0.3 mg/kg after iv and po administration respectively. Furthermore, antagonist 71 was found to be a potent inhibitor of SP-induced bronchoconstriction in guinea-pigs with an ED50 between 0.1 and 0.03 mg/kg iv. Furthermore, upon oral administration, 71 was observed to be active in a model of SP-induced bronchial hypersensitivity in mice, with an ID50 of around 3 mg/kg.

N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds

Compounds are disclosed of the formula STR1 optically active isomeric forms thereof, and/or pharmaceutically acceptable acid addition salts thereof, in which formula: R is defined in the disclosure.